Cost of screening and timely treatment versus the comprehensive management of the severe visual impairment due to retinopathy of premature

Visual abstract

PDF (Español (España))
PDF

Keywords

Retinopathy of Prematurity
Low Vision
Blindness
Cost of Illness
Neonatology
Ophthalmology
Screening Test
Preterm Infants

How to Cite

1.
del Busto Wilhelm E, Zimmermann Paiz MA, Ordóñez Rivas AM, Quezada del Cid NC, Burgos Elías VY, Rousselin Monterroso AA. Cost of screening and timely treatment versus the comprehensive management of the severe visual impairment due to retinopathy of premature. Andes pediatr [Internet]. 2023 Jun. 15 [cited 2025 Nov. 18];94(3):333-8. Available from: https://andespediatrica.cl/index.php/rchped/article/view/4530

Cited by


Abstract

Retinopathy of prematurity (ROP) is one of the leading causes of preventable blindness worldwide. In Guatemala, a large number of premature infants are born in hospitals outside the capital city and present for evaluation at advanced stages of the disease. 

Objective: To compare the cost of screening and timely treatment versus the total cost of comprehensive management of patients with visual impairment secondary to ROP. 

Patients and Method: The cost of the disease was calculated in patients who consulted due to low vision or blindness secondary to ROP. Direct costs were calculated based on those directly related to the management of the disease: medical care, rehabilitation, education, technical support, transportation, personal assistance, adaptations, and home equipment, compared with the costs of screening and timely treatment. 

Results: The total cost of managing a child with severe visual impairment due to ROP is USD 214,666.37 and the cost of screening and timely treatment is USD 1,223.12, meaning an additional cost of USD 213,443.24 in patients who were not screened and treated on time. Conclusion: The cost of screening and timely treatment represents only 0.57% of the total cost of lifelong management of a child with severe visual impairment.

https://doi.org/10.32641/andespediatr.v94i3.4530
PDF (Español (España))
PDF

Los contenidos publicados en esta revista están protegidos bajo una Licencia Creative Commons Atribución 4.0 Internacional (CC BY 4.0). Esto significa que cualquier persona es libre de compartir,  usar y construir a partir de este artículo, incluso con fines comerciales, siempre que se otorgue el crédito apropiado al autor original, se proporcione un enlace a la licencia, se indique el nombre y edición de la Revista.

Esta licencia no impone restricciones adicionales, lo que garantiza la libre circulación y reutilización del conocimiento con respeto y transparencia hacia los derechos de los autores.  (Véase El efecto del acceso abierto).